Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Nobel Laureate for Chemistry to visit UFS
2017-10-28

Description: Prof Levitt read more Tags: Prof Levitt read more

Prof Michael Levitt will be hosted by the UFS from
14 to 16 November 2017, where he will present the
first lecture in the Vice-Chancellor’s
Prestige Lecture Series.
Photo: Supplied

It is a great honour for the University of the Free State (UFS) to host Prof Michael Levitt, recipient of the 2013 Nobel Prize for Chemistry, which he shares with Marti Karplus and Arieh Warshel.

The trio received the Nobel Prize for their development of multiscale models used for complex chemical systems. “Being awarded the Nobel Prize is a unique and marvellous experience that no one can prepare for or could in any way know what to except,” said Prof Levitt during his 2013 Nobel Lecture at the Stanford University School of Medicine.

First lecture in Vice-Chancellor’s lecture series

The South African-born Nobel Laureate and Academy of Science of South Africa (ASSAf) Visiting Scholar will present the first lecture, Birth and Future of Multiscale Modelling of Macromolecules, in the Vice-Chancellors Prestige Lecture Series at the UFS on 14 November 2017. Prof Levitt is well-known for developing approaches which predict macromolecular structures.

He is one of many distinguished academics invited annually by ASSAf to deliver lectures as part of the Distinguished Visiting Scholars’ Programme, presented by ASSAf at universities across the country.

Pioneer in research of molecular dynamics

Prof Levitt is a biophysicist and a professor of Biology at Stanford University. He was one of the earliest researchers to conduct research on molecular dynamics stimulations of DNA and proteins. “My post-prize ambitions are twofold and probably inconsistent: (1) Work single-mindedly as I did in the mid-1970s on hard problems, and (2) Help today’s young scientists gain the recognition and independence which my generation enjoyed,” said Prof Levitt.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept